Uwe Zeymer
A5085798844- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Mechanical Circulatory Support Devices
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiac Structural Anomalies and Repair
- Heart Failure Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- Cardiac Health and Mental Health
- Cardiac Arrhythmias and Treatments
- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Cardiac pacing and defibrillation studies
- Cerebrovascular and Carotid Artery Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Lipoproteins and Cardiovascular Health
- Peripheral Artery Disease Management
- Acute Ischemic Stroke Management
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Klinikum Ludwigshafen
2016-2025
Stiftung Institut für Herzinfarktforschung
2016-2025
University of Freiburg
2025
Universitäts-Herzzentrum Freiburg-Bad Krozingen
2004-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024
German Cardiac Society
2011-2024
IRCCS Ospedale San Raffaele
2024
München Klinik
2023
Newcastle upon Tyne Hospitals NHS Foundation Trust
2022
Newcastle University
2022
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force European Society Cardiology (ESC)
In current international guidelines, intraaortic balloon counterpulsation is considered to be a class I treatment for cardiogenic shock complicating acute myocardial infarction. However, evidence based mainly on registry data, and there paucity of randomized clinical trials.
Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients atrial fibrillation, but this associated a high risk bleeding.
In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means percutaneous coronary intervention (PCI) improves outcomes. However, majority shock multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly assigned 706 had infarction, to one two initial strategies: either lesion only, option staged lesions, or immediate PCI....
Patient access to reperfusion therapy and the use of primary percutaneous coronary intervention (p-PCI) or thrombolysis (TL) varies considerably between European countries. The aim this study was obtain a realistic contemporary picture how patients with ST elevation myocardial infarction (STEMI) are treated in different chairpersons national working groups/societies interventional cardiology countries selected experts known be involved registries joined writing group upon invitation. Data...
The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE).Prospective cohort 3116 adult (2470 from Europe, 646 non-ESC countries), admitted 156 hospitals in 40 countries between January 2016 March 2018 a diagnosis IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed (18F-FDG PET/CT)] data were...
Abstract The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic failure, but whether also improves clinical outcomes when initiated who are hospitalized for acute is unknown. In this double-blind trial (EMPULSE; NCT04157751 ), 530 a primary diagnosis de novo decompensated regardless left ventricular ejection fraction were randomly assigned to receive 10 mg once daily placebo. Patients...
The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration improve coronary reperfusion and clinical outcome is unknown.
Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke thrombo-embolism, this common cardiac arrhythmia represents major healthcare burden in Europe.1 Stroke prevention is central to the management AF patients, with 2012 focused update European Society Cardiology (ESC) guidelines2 recommending oral anticoagulation (OAC) using well-controlled adjusted dose vitamin K antagonists (VKAs, e.g. warfarin) or non-VKA anticoagulants (NOACs, previously referred as...
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding death in patients undergoing primary percutaneous coronary intervention (PCI). Whether these benefits persist contemporary practice characterized by prehospital initiation treatment, optional use inhibitors novel P2Y12 radial-artery PCI access is unknown.We randomly assigned 2218 ST-segment elevation myocardial infarction (STEMI) who were being transported for receive either...
Percutaneous mechanical circulatory support devices are increasingly used in acute myocardial infarction complicated by cardiogenic shock (AMI-CS), despite limited evidence for their effectiveness. The aim of this study was to evaluate outcomes associated with use the Impella device compared intra-aortic balloon pump (IABP) and medical treatment patients AMI-CS. Data AMI-CS treated at European tertiary care hospitals were collected retrospectively. All underwent early revascularization...
β-Blockers remain the standard of care after a myocardial infarction (MI). However, benefit β-blocker use in patients with coronary artery disease (CAD) but no history MI, those remote and only risk factors for CAD is unclear.To assess association cardiovascular events stable prior CAD.Longitudinal, observational study Reduction Atherothrombosis Continued Health (REACH) registry who were divided into 3 cohorts: known MI (n = 14,043), without 12,012), or 18,653). Propensity score matching was...
Extracorporeal life support (ECLS) is increasingly used in the treatment of infarct-related cardiogenic shock despite a lack evidence regarding its effect on mortality. Download PDF Research Summary. In this multicenter trial, patients with acute myocardial infarction complicated by for whom early revascularization was planned were randomly assigned to receive ECLS plus usual medical (ECLS group) or alone (control group). The primary outcome death from any cause at 30 days. Safety outcomes...
Bleeding has recently emerged as an important outcome in the management of acute coronary syndromes (ACS), which is relatively frequent compared with ischaemic outcomes and implications terms prognosis, outcomes, costs. In particular, there evidence that patients experiencing major bleeding phase are at higher risk for death following months, although causal nature this relation still debated. This position paper aims to summarize current knowledge regarding epidemiology ACS percutaneous...
Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found be lower percutaneous intervention (PCI) culprit lesion only than immediate PCI. We evaluated clinical outcomes 1 year.
Background: The role of intraaortic balloon counterpulsation (IABP) in cardiogenic shock is still a subject intense debate despite the neutral results IABP-SHOCK II trial (Intraaortic Balloon Pump Cardiogenic Shock II) with subsequent downgrading international guidelines. So far, randomized data on impact IABP long-term clinical outcomes patients complicating acute myocardial infarction are lacking. Furthermore, only limited evidence available general treated by contemporary practice....
Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence ST-segment elevation are unclear.In this multicenter trial, we randomly assigned 554 with successfully arrest possible origin to undergo either immediate (immediate-angiography group) or initial intensive care assessment delayed selective (delayed-angiography group). All had no on...
This study aimed to assess the safety and effectiveness of renal denervation using Symplicity system in real-world patients with uncontrolled hypertension (NCT01534299). The Global SYMPLICITY Registry is a prospective, open-label, multicenter registry. Office 24-hour ambulatory blood pressures (BPs) were measured. Change from baseline 6 months was analyzed for all subgroups based on office systolic BP, diabetic status, function; cohort severe (office pressure, ≥160 mm Hg; ≥135 ≥3...